Galmed Pharmaceuticals (GLMD) Cash from Financing Activities (2013 - 2025)

Galmed Pharmaceuticals' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at $1.2 million for Q4 2025.

• In Q4 2025, Cash from Financing Activities rose 165.18% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $9.0 million (up 1461.59% YoY), while the FY2025 annual figure was $9.0 million, up 2.73% from the prior year.
• Cash from Financing Activities was $1.2 million for Q4 2025 at Galmed Pharmaceuticals, up from $289000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $17.4 million in Q1 2021 to a low of $130000.0 in Q1 2023.
• Historically, Cash from Financing Activities has averaged $3.4 million across 5 years, with a median of $818000.0 in 2024.
• The sharpest annual moves came in 2021 and 2022: Cash from Financing Activities jumped 28372.13% in 2021, then plunged 98.99% in 2022.
• A 5-year view of Cash from Financing Activities shows it stood at $17.4 million in 2021, then slumped by 98.99% to $175000.0 in 2022, then decreased by 25.71% to $130000.0 in 2023, then soared by 244.62% to $448000.0 in 2024, then soared by 165.18% to $1.2 million in 2025.
• The last three Cash from Financing Activities figures came in at $1.2 million (Q4 2025), $289000.0 (Q3 2025), and $6.0 million (Q2 2025), per Business Quant data.